Detalhe da pesquisa
1.
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.
Cell
; 185(3): 563-575.e11, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35120664
2.
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.
CA Cancer J Clin
; 69(5): 402-429, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31283845
3.
Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma.
Mod Pathol
; 37(3): 100420, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38185249
4.
Neurofibromatosis Type 2-Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif Dual Immunohistochemistry Is a Reliable Marker for the Detection of Neurofibromatosis Type 2 Alterations in Diffuse Pleural Mesothelioma.
Mod Pathol
; 36(3): 100030, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36788094
5.
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.
Lancet Oncol
; 23(6): 758-767, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35588752
6.
Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma.
Invest New Drugs
; 39(4): 1081-1088, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33660194
7.
V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
Mod Pathol
; 33(2): 303-311, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31537897
8.
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.
Invest New Drugs
; 38(2): 457-467, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31065954
9.
Workshop summary: Potential usefulness and feasibility of a US National Mesothelioma Registry.
Am J Ind Med
; 63(2): 105-114, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31743489
10.
Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography?
J Comput Assist Tomogr
; 42(4): 601-606, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29613986
11.
ARCS-M: forging progress from this negative trial in malignant pleural mesothelioma.
Lancet Oncol
; 23(4): 445-446, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35358447
12.
Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice.
Oncologist
; 27(8): 610-614, 2022 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35708504
13.
Diffuse Pleural Mesothelioma: Advances in Molecular Pathogenesis, Diagnosis, and Treatment.
Annu Rev Pathol
; 19: 11-42, 2024 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37722697
14.
Diffuse pleural mesotheliomas with genomic near-haploidization: a newly recognized subset with distinct clinical, histologic, and molecular features.
Clin Cancer Res
; 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38630790
15.
Clinical outcomes of stereotactic body radiation therapy for malignant pleural mesothelioma.
Radiother Oncol
; 191: 110057, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38104783
16.
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.
JAMA Oncol
; 10(4): 475-483, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38358753
17.
Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma.
Front Immunol
; 14: 1112960, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36875061
18.
Reliability of assessing morphologic features with prognostic significance in cytology specimens of epithelioid diffuse pleural mesothelioma and implications for cytopathology reporting.
Cancer Cytopathol
; 131(8): 495-506, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37127928
19.
Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma.
JAMA Netw Open
; 6(3): e232526, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36897589
20.
A Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural Mesothelioma.
JTO Clin Res Rep
; 4(1): 100440, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36590015